person · Reporting owner

LANGE LOUIS G

Disclosed activity across 5 companies

Tapewire entity: 17051
SEC CIK: 0001238401

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BioPlus Acquisition Corp.BIOS · Entity 112459	Director	December 02, 2021	December 02, 2021
Epiphany Technology Acquisition Corp.EPHY · Entity 123266	Director	September 16, 2022	October 04, 2022
NewAmsterdam Pharma Co N.V.NAMS · Entity 1826	Director	March 11, 2026	March 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BioPlus Acquisition Corp.

Report date December 02, 2021 · Filed December 02, 2021

This filing explicitly reported no securities owned.

Epiphany Technology Acquisition Corp.

Report date September 16, 2022 · Filed October 04, 2022

This filing explicitly reported no securities owned.

NewAmsterdam Pharma Co N.V.

Report date March 11, 2026 · Filed March 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	10,360	Ending reported balance After 2026-03-11 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-03-11 · Sale · Disposed 44,173 · Balance 10,806 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.11 per share to $31.08 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Row 2 · 2026-03-11 · Sale · Disposed 446 · Balance 10,360 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.13 per share to $31.31 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.11 per share to $31.08 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.13 per share to $31.31 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Audentes Therapeutics, Inc.

Report date January 15, 2020 · Filed January 15, 2020

Section 16 reporting ended · disclosed 2020-01-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-01-15 transaction · row 1 1 source row Row 1 · 2020-01-15 · Other · Disposed 265,799 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price.
Common StockSEC Table I · non-derivative	IndirectBy Amygdala Lange Trust	Reported balance After 2020-01-15 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2020-01-15 · Other · Disposed 13,678 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2: The reporting person's spouse is the trustee of the Amygdala Lange Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
Common StockSEC Table I · non-derivative	IndirectBy Asset Management Ventures Fund, L.P.	Reported balance After 2020-01-15 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2020-01-15 · Other · Disposed 32,343 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F3: The reporting person is a general partner of Asset Management Ventures Fund, L.P. ("AMVF L.L.P."), and has shared voting and dispositive power over the shares held by AMVF L.L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Common StockSEC Table I · non-derivative	IndirectBy Adrienne M. MacMillan Revocable Trust(	Reported balance After 2020-01-15 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2020-01-15 · Other · Disposed 3,555 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F4: The reporting person's spouse is the trustee of the Adrienne M. MacMillan Revocable Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.03 · Expires 2026-08-24	Direct	Reported balance After 2020-01-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-01-15 · Disposition to issuer · Disposed 18,000 · Balance 0 F5: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.15 · Expires 2027-10-08	Direct	Reported balance After 2020-01-15 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-01-15 · Disposition to issuer · Disposed 9,000 · Balance 0 F6: Reflects the correct exercise price of this option. The exercise price of this option was previously reported as $26.01. F5: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.65 · Expires 2028-06-08	Direct	Reported balance After 2020-01-15 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-01-15 · Disposition to issuer · Disposed 10,000 · Balance 0 F5: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.74 · Expires 2029-02-06	Direct	Reported balance After 2020-01-15 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-01-15 · Disposition to issuer · Disposed 16,200 · Balance 0 F5: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price.

F2: The reporting person's spouse is the trustee of the Amygdala Lange Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

F3: The reporting person is a general partner of Asset Management Ventures Fund, L.P. ("AMVF L.L.P."), and has shared voting and dispositive power over the shares held by AMVF L.L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

F4: The reporting person's spouse is the trustee of the Adrienne M. MacMillan Revocable Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.

F5: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.

F6: Reflects the correct exercise price of this option. The exercise price of this option was previously reported as $26.01.

GILEAD SCIENCES, INC.

Report date June 01, 2009 · Filed June 05, 2009

Section 16 reporting ended · disclosed 2009-06-05. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 11, 2026 Filed Mar 12, 2026 20:25 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	446	$31.23	$13,928.58	Disclosure SEC source: 0001193125-26-104239 · ownership.xml · nonDerivative · entry 2 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,360 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.13 per share to $31.31 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document
March 11, 2026 Filed Mar 12, 2026 20:25 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	44,173	$30.41	$1,343,300.93	Disclosure SEC source: 0001193125-26-104239 · ownership.xml · nonDerivative · entry 1 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,806 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.11 per share to $31.08 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document
March 09, 2026 Filed Mar 11, 2026 00:58 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	OtherWarrant (right to buy) · Derivative	44,619	$0.00 Strike: $11.50	$0.00	Disclosure SEC source: 0001193125-26-100798 · ownership.xml · derivative · entry 3 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 44,619 shares Expires 2027-11-23 Read SEC document
March 09, 2026 Filed Mar 11, 2026 00:58 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	OtherOrdinary Shares	44,619	$11.50	$513,118.50	Disclosure SEC source: 0001193125-26-100798 · ownership.xml · nonDerivative · entry 2 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,979 Read SEC document
March 06, 2026 Filed Mar 11, 2026 00:58 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	SaleOrdinary Shares	28,186	$29.41	$828,950.26	Disclosure SEC source: 0001193125-26-100798 · ownership.xml · nonDerivative · entry 1 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.03 per share to $29.68 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. F2 · ownership.nature: The shares are held directly by LGLange III Trust DTD10 (the "Trust") for the benefit of the Reporting Person. Read SEC document
January 07, 2026 Filed Jan 10, 2026 00:33 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	GrantOption (right to buy) · Derivative	15,300	$0.00 Strike: $35.45	$0.00	Disclosure SEC source: 0001193125-26-009268 · ownership.xml · derivative · entry 2 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,300 Underlying: Ordinary Shares · 15,300 shares Expires 2036-01-07 F4 · derivative.exercise_date: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. Read SEC document
January 07, 2026 Filed Jan 10, 2026 00:33 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	GrantOrdinary Shares	3,400	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-009268 · ownership.xml · nonDerivative · entry 1 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,360 F1 · shares: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. F2 · price: Each RSU was granted on January 7, 2026 for no consideration. F3 · balance_after: The Reporting Person inadvertently reported the ownership of 3,102 ordinary shares issued upon vesting of RSUs on March 28, 2025 to his direct holdings. Such ordinary shares are held directly by LGLange III Trust DTD10 for the benefit of the Reporting Person. The Reporting Person subsequently corrected his indirect holdings on April 21, 2025, and the Reporting Person's indirect holdings reported on May 2, 2025 and June 3, 2025 are correct. This Form 4 reflects the Reporting Person's correct direct holdings. Read SEC document
June 01, 2025 Filed Jun 3, 2025 20:59 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	Exercise / conversionRestricted Stock Unit · Derivative	68	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-081072 · ownership.xml · derivative · entry 2 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 68 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share. F4 · price: The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date under the BCA (the "Closing Date"). The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date. F3 · derivative.exercise_date: 3,102 RSUs vested upon grant, 69 RSUs vested on April 1, 2025,69 RSUs vested on May 1, 2025 and 68 RSUs vested on June 1, 2025. F3 · derivative.expiration_date: 3,102 RSUs vested upon grant, 69 RSUs vested on April 1, 2025,69 RSUs vested on May 1, 2025 and 68 RSUs vested on June 1, 2025. Read SEC document
June 01, 2025 Filed Jun 3, 2025 20:59 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	Exercise / conversionOrdinary Shares	68	$0.00	$0.00	Disclosure SEC source: 0000950170-25-081072 · ownership.xml · nonDerivative · entry 1 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 28,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The shares are held directly by LGLange III Trust DTD10 (the "Trust") for the benefit of the Reporting Person. Read SEC document
May 01, 2025 Filed May 2, 2025 20:55 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	Exercise / conversionRestricted Stock Unit · Derivative	69	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-062894 · ownership.xml · derivative · entry 2 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68 Underlying: Ordinary Shares · 69 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share. F4 · price: The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date under the BCA (the "Closing Date"). The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date. F3 · derivative.exercise_date: 3,102 RSUs vested upon grant, 69 RSUs vested on April 1, 2025 and 69 RSUs vested on May 1, 2025. The 68 remaining RSUs will vest on June 1, 2025, subject to the Reporting Person's continued service with the issuer as of each of the vesting date. F3 · derivative.expiration_date: 3,102 RSUs vested upon grant, 69 RSUs vested on April 1, 2025 and 69 RSUs vested on May 1, 2025. The 68 remaining RSUs will vest on June 1, 2025, subject to the Reporting Person's continued service with the issuer as of each of the vesting date. Read SEC document
May 01, 2025 Filed May 2, 2025 20:55 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	Exercise / conversionOrdinary Shares	69	$0.00	$0.00	Disclosure SEC source: 0000950170-25-062894 · ownership.xml · nonDerivative · entry 1 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 28,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The shares are held directly by LGLange III Trust DTD10 (the "Trust") for the benefit of the Reporting Person. Read SEC document
April 14, 2025 Filed Apr 21, 2025 21:41 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	Exercise / conversionRestricted Stock Unit · Derivative	69	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-056395 · ownership.xml · derivative · entry 2 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137 Underlying: Ordinary Shares · 69 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share. F4 · price: The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date. F3 · derivative.exercise_date: 3,102 RSUs vested upon grant and 69 RSUs vested on April 1, 2025. The remaining RSUs will vest as follows, subject to the Reporting Person's continued service with the issuer as of each of the applicable vesting dates: 69 of the remaining RSUs will vest on May 1, 2025 and 68 of the remaining RSUs will vest on June 1, 2025. F3 · derivative.expiration_date: 3,102 RSUs vested upon grant and 69 RSUs vested on April 1, 2025. The remaining RSUs will vest as follows, subject to the Reporting Person's continued service with the issuer as of each of the applicable vesting dates: 69 of the remaining RSUs will vest on May 1, 2025 and 68 of the remaining RSUs will vest on June 1, 2025. Read SEC document
April 14, 2025 Filed Apr 21, 2025 21:41 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	Exercise / conversionOrdinary Shares	69	$0.00	$0.00	Disclosure SEC source: 0000950170-25-056395 · ownership.xml · nonDerivative · entry 1 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 28,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: The shares are held directly by LGLange III Trust DTD10 (the "Trust") for the benefit of the Reporting Person. The Reporting Person inadvertently reported the ownership of 3,102 ordinary shares issued upon vesting of restricted stock units ("RSUs") on March 28, 2025 to his direct holdings. Such ordinary shares are held by the Trust, and this Form 4 reflects the Reporting Person's correct direct and indirect holdings. Read SEC document
March 26, 2025 Filed Mar 28, 2025 21:24 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	Exercise / conversionRestricted Stock Unit · Derivative	3,102	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-046958 · ownership.xml · derivative · entry 3 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206 Underlying: Ordinary Shares · 3,102 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share. F3 · price: The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date. F2 · derivative.exercise_date: Upon grant, 3,102 RSUs were fully-vested. The remaining RSUs will vest as follows, subject to the Reporting Person's continued service with the Company as of each of the applicable vesting dates: 69 of the remaining RSUs will vest on April 1, 2025; 69 of the remaining RSUs will vest on May 1, 2025; and 68 of the remaining RSUs will vest on June 1, 2025. F2 · derivative.expiration_date: Upon grant, 3,102 RSUs were fully-vested. The remaining RSUs will vest as follows, subject to the Reporting Person's continued service with the Company as of each of the applicable vesting dates: 69 of the remaining RSUs will vest on April 1, 2025; 69 of the remaining RSUs will vest on May 1, 2025; and 68 of the remaining RSUs will vest on June 1, 2025. Read SEC document
March 26, 2025 Filed Mar 28, 2025 21:24 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	GrantRestricted Stock Unit · Derivative	3,308	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-046958 · ownership.xml · derivative · entry 2 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,308 Underlying: Ordinary Shares · 3,308 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share. F3 · price: The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date. F2 · derivative.exercise_date: Upon grant, 3,102 RSUs were fully-vested. The remaining RSUs will vest as follows, subject to the Reporting Person's continued service with the Company as of each of the applicable vesting dates: 69 of the remaining RSUs will vest on April 1, 2025; 69 of the remaining RSUs will vest on May 1, 2025; and 68 of the remaining RSUs will vest on June 1, 2025. F2 · derivative.expiration_date: Upon grant, 3,102 RSUs were fully-vested. The remaining RSUs will vest as follows, subject to the Reporting Person's continued service with the Company as of each of the applicable vesting dates: 69 of the remaining RSUs will vest on April 1, 2025; 69 of the remaining RSUs will vest on May 1, 2025; and 68 of the remaining RSUs will vest on June 1, 2025. Read SEC document
March 26, 2025 Filed Mar 28, 2025 21:24 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	Exercise / conversionOrdinary Shares	3,102	$0.00	$0.00	Disclosure SEC source: 0000950170-25-046958 · ownership.xml · nonDerivative · entry 1 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 07, 2025 Filed Jan 8, 2025 22:57 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	GrantOrdinary Shares	6,960	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-003552 · ownership.xml · nonDerivative · entry 1 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,960 F1 · shares: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date. F2 · price: Each RSU was granted on January 7, 2025 for no consideration. Read SEC document
January 06, 2025 Filed Jan 8, 2025 22:57 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	GrantOption (right to buy) · Derivative	32,500	$0.00 Strike: $25.85	$0.00	Disclosure SEC source: 0000950170-25-003552 · ownership.xml · derivative · entry 3 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 Underlying: Ordinary Shares · 32,500 shares Expires 2035-01-06 F4 · derivative.exercise_date: 1/3 of the shares underlying the option will vest on January 6, 2026, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for two years, subject to the Reporting Person's continued service through each such date. Read SEC document
February 13, 2024 Filed Feb 21, 2024 22:00 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	PurchaseOrdinary Shares	5,000	$19.00	$95,000.00	Disclosure SEC source: 0000950170-24-018045 · ownership.xml · nonDerivative · entry 1 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 24,878 F1 · ownership.nature: Represents ordinary shares acquired from the Company in an underwritten public offering. The ordinary shares acquired from the Company were placed into and are being held in a trust account for the benefit of the Reporting Person. Read SEC document
January 01, 2024 Filed Jan 3, 2024 22:17 UTC	NewAmsterdam Pharma Co N.V. NAMS · Entity 1826	GrantOption (right to buy) · Derivative	10,000	$0.00 Strike: $11.17	$0.00	Disclosure SEC source: 0000950170-24-001128 · ownership.xml · derivative · entry 1 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of the shares underlying the option will vest on January 1, 2025, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:31 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	Disposition to issuerStock Option (Right to Buy) · Derivative	16,200	Not disclosed Strike: $24.74	Not disclosed	Disclosure SEC source: 0001209191-20-003430 · doc4.xml · derivative · entry 8 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,200 shares Expires 2029-02-06 F5 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:31 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	Not disclosed Strike: $38.65	Not disclosed	Disclosure SEC source: 0001209191-20-003430 · doc4.xml · derivative · entry 7 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-06-08 F5 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:31 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	Disposition to issuerStock Option (Right to Buy) · Derivative	9,000	Not disclosed Strike: $26.15	Not disclosed	Disclosure SEC source: 0001209191-20-003430 · doc4.xml · derivative · entry 6 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2027-10-08 F6 · derivative.exercise_price: Reflects the correct exercise price of this option. The exercise price of this option was previously reported as $26.01. F5 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:31 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	Disposition to issuerStock Option (Right to Buy) · Derivative	18,000	Not disclosed Strike: $15.03	Not disclosed	Disclosure SEC source: 0001209191-20-003430 · doc4.xml · derivative · entry 5 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2026-08-24 F5 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:31 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	OtherCommon Stock	3,555	$60.00	$213,300.00	Disclosure SEC source: 0001209191-20-003430 · doc4.xml · nonDerivative · entry 4 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Adrienne M. MacMillan Revocable Trust( Disclosed balance after: 0 F1 · kind: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F4 · ownership.nature: The reporting person's spouse is the trustee of the Adrienne M. MacMillan Revocable Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:31 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	OtherCommon Stock	32,343	$60.00	$1,940,580.00	Disclosure SEC source: 0001209191-20-003430 · doc4.xml · nonDerivative · entry 3 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Asset Management Ventures Fund, L.P. Disclosed balance after: 0 F1 · kind: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F3 · ownership.nature: The reporting person is a general partner of Asset Management Ventures Fund, L.P. ("AMVF L.L.P."), and has shared voting and dispositive power over the shares held by AMVF L.L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:31 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	OtherCommon Stock	13,678	$60.00	$820,680.00	Disclosure SEC source: 0001209191-20-003430 · doc4.xml · nonDerivative · entry 2 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Amygdala Lange Trust Disclosed balance after: 0 F1 · kind: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2 · ownership.nature: The reporting person's spouse is the trustee of the Amygdala Lange Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:31 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	OtherCommon Stock	265,799	$60.00	$15,947,940.00	Disclosure SEC source: 0001209191-20-003430 · doc4.xml · nonDerivative · entry 1 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. Read SEC document
December 23, 2019 Filed Dec 27, 2019 16:10 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	SaleCommon Stock	1,000	$59.60	$59,596.30	Disclosure SEC source: 0001209191-19-062016 · doc4.xml · nonDerivative · entry 2 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Amygdala Lange Trust Disclosed balance after: 13,678 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $59.55 and the highest price at which shares were sold was $59.65. F4 · ownership.nature: The reporting person's spouse is the trustee of the Amygdala Lange Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document
December 23, 2019 Filed Dec 27, 2019 16:10 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	SaleCommon Stock	10,000	$59.60	$595,993.00	Disclosure SEC source: 0001209191-19-062016 · doc4.xml · nonDerivative · entry 1 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,799 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $59.56 and the highest price at which shares were sold was $59.70. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document
September 23, 2019 Filed Sep 25, 2019 18:11 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	SaleCommon Stock	1,000	$32.18	$32,182.00	Disclosure SEC source: 0001209191-19-050729 · doc4.xml · nonDerivative · entry 3 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Amygdala Lange Trust Disclosed balance after: 14,678 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $31.68 and the highest price at which shares were sold was $32.60. F5 · ownership.nature: The reporting person's spouse is the trustee of the Amygdala Lange Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document
September 23, 2019 Filed Sep 25, 2019 18:11 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	SaleCommon Stock	245	$32.66	$8,002.39	Disclosure SEC source: 0001209191-19-050729 · doc4.xml · nonDerivative · entry 2 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,799 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $32.615 and the highest price at which shares were sold was $32.705. Read SEC document
September 23, 2019 Filed Sep 25, 2019 18:11 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	SaleCommon Stock	9,755	$32.15	$313,613.50	Disclosure SEC source: 0001209191-19-050729 · doc4.xml · nonDerivative · entry 1 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,044 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $31.61 and the highest price at which shares were sold was $32.59. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document
June 24, 2019 Filed Jun 26, 2019 16:07 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	SaleCommon Stock	200	$39.46	$7,892.00	Disclosure SEC source: 0001209191-19-039082 · doc4.xml · nonDerivative · entry 5 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Amygdala Lange Trust Disclosed balance after: 15,678 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $39.31 and the highest price at which shares were sold was $39.61 F6 · ownership.nature: The reporting person's spouse is the trustee of the Amygdala Lange Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document
June 24, 2019 Filed Jun 26, 2019 16:07 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	SaleCommon Stock	800	$37.89	$30,308.80	Disclosure SEC source: 0001209191-19-039082 · doc4.xml · nonDerivative · entry 4 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Amygdala Lange Trust Disclosed balance after: 15,878 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $37.37 and the highest price at which shares were sold was $38.30. F6 · ownership.nature: The reporting person's spouse is the trustee of the Amygdala Lange Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document
June 24, 2019 Filed Jun 26, 2019 16:07 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	SaleCommon Stock	600	$40.00	$23,998.50	Disclosure SEC source: 0001209191-19-039082 · doc4.xml · nonDerivative · entry 3 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,799 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $39.88 and the highest price at which shares were sold was $40.41. Read SEC document
June 24, 2019 Filed Jun 26, 2019 16:07 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	SaleCommon Stock	3,602	$38.15	$137,409.46	Disclosure SEC source: 0001209191-19-039082 · doc4.xml · nonDerivative · entry 2 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,399 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $38.76 and the highest price at which shares were sold was $39.70. Read SEC document
June 24, 2019 Filed Jun 26, 2019 16:07 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	SaleCommon Stock	15,798	$37.60	$594,004.80	Disclosure SEC source: 0001209191-19-039082 · doc4.xml · nonDerivative · entry 1 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,001 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $37.39 and the highest price at which shares were sold was $38.34. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (7) to this Form 4. Read SEC document
March 25, 2019 Filed Mar 27, 2019 17:03 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	SaleCommon Stock	558	$35.94	$20,054.69	Disclosure SEC source: 0001209191-19-021433 · doc4.xml · nonDerivative · entry 4 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Lange Minor's Trust Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $35.71 and the highest price at which shares were sold was $36.15. F7 · ownership.nature: The reporting person's spouse is the trustee of the Lange Minor's Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document
March 25, 2019 Filed Mar 27, 2019 17:03 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	SaleCommon Stock	1,000	$36.00	$36,003.70	Disclosure SEC source: 0001209191-19-021433 · doc4.xml · nonDerivative · entry 3 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Amygdala Lange Trust Disclosed balance after: 16,678 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: Represents the average weighted sale price. The lowest price at which shares were sold was $35.63 and the highest price at which shares were sold was $36.19. F5 · ownership.nature: The reporting person's spouse is the trustee of the Amygdala Lange Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document
March 25, 2019 Filed Mar 27, 2019 17:03 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	SaleCommon Stock	300	$36.64	$10,992.18	Disclosure SEC source: 0001209191-19-021433 · doc4.xml · nonDerivative · entry 2 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,799 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $36.51 and the highest price at which shares were sold was $36.86. Read SEC document
March 25, 2019 Filed Mar 27, 2019 17:03 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	SaleCommon Stock	19,700	$35.99	$709,022.70	Disclosure SEC source: 0001209191-19-021433 · doc4.xml · nonDerivative · entry 1 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,099 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $35.45 and the highest price at which shares were sold was $36.41. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (6) to this Form 4. Read SEC document
February 06, 2019 Filed Feb 8, 2019 17:22 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	GrantStock Option (right to buy) · Derivative	16,200	$0.00 Strike: $24.74	$0.00	Disclosure SEC source: 0001209191-19-008667 · doc4.xml · derivative · entry 1 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,200 Underlying: Common Stock · 16,200 shares Expires 2029-02-06 F1 · derivative.exercise_date: The option vests as to 100% of the shares upon the earlier of (i) the one-year anniversary of the grant date, and (ii) a Corporate Transaction of the Company as defined in the Company's 2016 Equity Incentive Plan; subject to the reporting person's continued service to the Company on the vesting date. Read SEC document
December 24, 2018 Filed Dec 27, 2018 17:43 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	SaleCommon Stock	10,000	$18.50	$184,951.00	Disclosure SEC source: 0001209191-18-064210 · doc4.xml · nonDerivative · entry 4 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Asset Management Ventures Fund, L.P. Disclosed balance after: 32,343 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $18.23 and the highest price at which shares were sold was $18.64. F7 · ownership.nature: The reporting person is a general partner of Asset Management Ventures Fund, L.P. ("AMVF L.L.P."), and has shared voting and dispositive power over the shares held by AMVF L.L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document
December 24, 2018 Filed Dec 27, 2018 17:43 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	SaleCommon Stock	1,000	$18.71	$18,713.00	Disclosure SEC source: 0001209191-18-064210 · doc4.xml · nonDerivative · entry 3 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Lange Minor's Trust Disclosed balance after: 558 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $18.40 and the highest price at which shares were sold was $18.98. F5 · ownership.nature: The reporting person's spouse is the trustee of the Lange Minor's Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document
December 24, 2018 Filed Dec 27, 2018 17:43 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	SaleCommon Stock	1,000	$18.70	$18,701.00	Disclosure SEC source: 0001209191-18-064210 · doc4.xml · nonDerivative · entry 2 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Amygdala Lange Trust Disclosed balance after: 17,678 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $18.40 and the highest price at which shares were sold was $18.98. F4 · ownership.nature: The reporting person's spouse is the trustee of the Amygdala Lange Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document
December 24, 2018 Filed Dec 27, 2018 17:43 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	SaleCommon Stock	20,000	$18.67	$373,434.00	Disclosure SEC source: 0001209191-18-064210 · doc4.xml · nonDerivative · entry 1 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,799 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $18.28 and the highest price at which shares were sold was $19.09. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (6) to this Form 4. Read SEC document
November 15, 2018 Filed Nov 16, 2018 18:34 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	SaleCommon Stock	4,000	$22.49	$89,960.00	Disclosure SEC source: 0001209191-18-059054 · doc4.xml · nonDerivative · entry 2 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Adrienne M. MacMillan Revocable Trust Disclosed balance after: 3,555 F1 · kind: The reporting person contributed shares of the Issuer's common stock to an exchange fund in exchange for shares of the exchange fund. The Issuer's common stock was valued at $22.49 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person. F1 · price: The reporting person contributed shares of the Issuer's common stock to an exchange fund in exchange for shares of the exchange fund. The Issuer's common stock was valued at $22.49 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person. F2 · ownership.nature: The reporting person's spouse is the trustee of the Adrienne M. MacMillan Revocable Trust. The reporting person disclaims beneficial ownership of such securities, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document
November 15, 2018 Filed Nov 16, 2018 18:34 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	SaleCommon Stock	20,000	$22.49	$449,800.00	Disclosure SEC source: 0001209191-18-059054 · doc4.xml · nonDerivative · entry 1 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,799 F1 · kind: The reporting person contributed shares of the Issuer's common stock to an exchange fund in exchange for shares of the exchange fund. The Issuer's common stock was valued at $22.49 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person. F1 · price: The reporting person contributed shares of the Issuer's common stock to an exchange fund in exchange for shares of the exchange fund. The Issuer's common stock was valued at $22.49 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person. Read SEC document
September 24, 2018 Filed Sep 26, 2018 19:00 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	SaleCommon Stock	10,000	$37.45	$374,536.00	Disclosure SEC source: 0001209191-18-052368 · doc4.xml · nonDerivative · entry 6 LANGE LOUIS G · CIK 0001238401 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Asset Management Ventures Fund, L.P. Disclosed balance after: 42,343 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $37.00 and the highest price at which shares were sold was $37.675. F10 · ownership.nature: The reporting person is a general partner of Asset Management Ventures Fund, L.P. ("AMVF L.L.P."), and has shared voting and dispositive power over the shares held by AMVF L.L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.